What is known about melatonin, chemotherapy and altered gene expression in breast cancer

Oncology Letters

Volumn 13, Issue 4, 2017, Pages 2003-2014

  Martínez Campa, Carlos ^a   Menéndez Menéndez, Javier ^a   Alonso González, Carolina ^a   González, Alicia ^a   Álvarez García, Virginia ^b   Cos, Samuel ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Cancer; Chemotherapy; Gene expression; Melatonin

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERIBULIN; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LAPATINIB; MELATONIN; METHOTREXATE; MITOXANTRONE; PRAVASTATIN; PROTEIN MDM2; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID; VINORELBINE TARTRATE;

ADJUVANT THERAPY; APOPTOSIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG OVERDOSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TRANSLATIONAL PROTEIN MODIFICATION; TUMOR GENE; TUMOR GROWTH;

EID: 85015332549     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.5712     Document Type: Review

References (155)

1. World Cancer Research Fund/American Institute for Cancer Research: Second Expert Report. http://www.wcrf.org/int/research-we-fund/continuous-update-project-cup/second-expertreport. Accessed August 14, 2016.
2. American Cancer Society: Cancer facts and figures 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015. Accessed August 14, 2016.
3. American Cancer Society: What are the key statistics about breast cancer? http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics. Accessed August 14, 2016.
4. Reynolds T: Declining breast cancer mortality: What's behind it? J Natl Cancer Inst 91: 750-753, 1999.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV; Writing Group for the Women's Health Initiative Investigators, et al: Risks and benefits of estrogens plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled trial. J Am Med Assoc 288: 321-333, 2002.
6. Greig RG and Trainer DL: Shaping future strategies for the pharmacological control of tumor cell metastases. Cancer Metastasis Rev 5: 3-14, 1986.
7. Perloff M and Holland JF: Surgical adjuvant chemotherapy. Ann Rev Med 28: 475-488, 1977.
8. Maughan KL, Lutterbie MA and Ham PS: Treatment of breast cancer. Am Fam Physician 81: 1339-1346, 2010.
9. Mamounas EP: Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol 22: 1425-1433, 2015.
10. Masood S: Neoadjuvant chemotherapy in breast cancers. Womens Health (Lond) 12: 480-491, 2016.
11. Suter R and Marcum JA: The molecular genetics of breast cancer and targeted therapy. Biologics 1: 241-258, 2007.
12. BreastCancer.Org. How is Chemotherapy Given? http://www.breastcancer.org/treatment/chemotherapy/process/how. Accessed August 14, 2016.
13. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
14. Moudi M, Go R, Yien CY and Nazre M: Vinca alcaloids. Int J Prev Med 4: 1231-1235, 2013.
15. Johnson IS, Armstrong JG, Gorman M and Burnett JP Jr: The Vinca Alkaloids: A new class of oncolytic agents, Cancer Res 23: 1390-1427, 1963.
16. Himes RH: Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51: 257-267, 1991.
17. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A and Knossow M: Structural basis for the regulation of tubulin by vinblastine. Nature 435: 519-522, 2005.
18. Graf E and Bertholdt H: Amorphous taxine & crystalline taxine A; Taxus alkaloids. II. Pharm Zentralhalle Dtschl 96: 385-395, 1957 (In German).
19. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agentes. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agente from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
20. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB and Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486-2493, 1987.
21. Bissery MC, Guénard D, Guéritte-Voegelein F and Lavelle F: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
22. Ringel I and Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
23. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, Fiser A, Horwitz SB and Orr GA: Insights into the mechanism of microtubule stabilization by Taxol. Proc Natl Acad Sci USA 103: 10166-10173, 2006.
24. Snyder JP, Nettles JH, Cornet B, Downing KH and Nogales E: The binding conformation of Taxol in beta-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci USA 98: 5312-5316, 2001.
25. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818-826, 1985.
26. Mizuno NS, Zakis B and Decker RW: Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis. Cancer Res 35: 1542-1546, 1975.
27. Andoh T: Inhibitors of DNA topoisomerases. Gan To Kagaku Ryoho 24: 1526-1535, 1997 (In Japanese).
28. Khasraw M, Bell R and Dang C: Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. Breast 21: 142-149, 2012.
29. US Food and Drug Administration. Advisory Committees: 2010 Meeting Materials, Oncologic Drugs Advisory Committee. http://www.cancer.gov/aboutcancer/treatment/drugs/fda-eribulinmesylate. Accessed November 28, 2016
30. Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ and Littlefield BA: Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 71: 496-505, 2011.
31. Marhold M, Bartsch R and Zielinski C: Recent developments and translational aspects in targeted therapy for metastatic breast cancer. ESMO Open 1: e000036, 2016.
32. Wong WM: Drug update: Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract 7: 48-50, 1999.
33. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998.
34. Mayer IA: Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer 9 (Suppl 2): S50-S57, 2009.
35. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N and Johnston S: Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: Final results and survival of the expanded HER2+ cohort in EGR103009, a phase II study. Lancet Oncol 10: 581-588, 2009.
36. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005, 2008.
37. Burris HA III: Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 (Suppl 3): S10-S15, 2004.
38. Burstein HJ, Sun Y, Dirix LI, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28: 1301-1307, 2010.
39. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, et al: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958-3965, 2004.
40. Darby JF and Workman P: Chemical biology: Many faces of a cancer-supporting protein. Nature 478: 334-335, 2011.
41. Hague A, Alam Q, Alam MZ, Azhar EI, Sait KH, Anfinan N, Mushtaq G, Kamal MA and Rasool M: Current understanding of HSP90 as a novel therapeutic target: An emerging approach for the treatment of cancer. Curr Pharm Des 22: 2947-2959, 2016.
42. Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J and Vereb G: Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 104: 146-155, 2006.
43. Beliakoff J and Whitesell L: Hsp90: An emerging target for breast cancer therapy. Anticancer Drugs 15: 651-662, 2004.
44. McDonald PC, Chafe SC and Dedhar S: Overcoming hypoxia-mediated tumor progression: Combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction. Front Cell Dev Biol 4: 27, 2016.
45. Rao N, Lee YE and Ge R: Novel endogenous angiogenesis inhibitors and their therapeutic potential. Acta Pharmacol Sin 36: 1177-1190, 2015.
46. Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE and de Vries EG: VEGF pathway targeting agents, vessel normalization and tumor drug uptake: From bench to bedside. Oncotarget 7: 21247-21258, 2016.
47. Kerbel RS: Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 17: 229-239, 2012.
48. Kerr DJ: Targeting angiogenesis in cancer: Clinical development of bevacizumab. Nat Clin Pract Oncol 1: 39-43, 2004.
49. Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Paterson AH, Robidoux A and Pritchard KI: Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials, Cancer Treat Rev 38: 673-688, 2012.
50. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
51. Sloan B and Scheinfeld NS: Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 9: 1324-1335, 2008.
52. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, Steinberg SM and Steeg PS: Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 17: 142-153, 2011.
53. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard KI and Leighl NB: A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the princess Margaret Hospital phase II consortium. Oncologist 15: 810-818, 2010.
54. Mauvais-Jarvis P, Kuttenn F and Gompel A: Estradiol/progesterone interaction in normal and pathological breast cells. Ann N Acad Sci 464: 152-167, 1986.
55. Lumachi F, Santeufemia DA and Basso SM: Current medical treatment of estrogen receptor-positive breast-cancer. World J Biol Chem 6: 231-239, 2015.
56. Ellis AJ, Hendrick VM, Williams R and Komm BS: Selective estrogen receptor modulators in clinical practice: A safety overview. Expert Opin Drug Saf 14: 921-934, 2015.
57. Jordan VC: Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer 21: R235-R246, 2014
58. Dalmau E, Armengol-Alonso A, Muñoz M and Seguí-Palmer MÁ: Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. Breast 23: 710-720, 2014.
59. Morris C and Wakeling A: Fulvestrant (‘Faslodex’)-a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 9: 267-276, 2002.
60. Johnston SJ and Cheung KL: Fulvestrant-a novel endocrine therapy for breast cancer. Curr Med Chem 17: 902-914, 2010.
61. Wong ZW and Ellis MJ: First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen? Br J Cancer 90: 20-25, 2004.
62. Reiter RJ, Tan DX and Fuentes-Broto L: Melatonin: A multitasking molecule. Prog Brain Res 181: 127-151, 2010.
63. Reiter RJ, Tan DX and Galano A: Melatonin: Exceeding expectations. Physiology (Bethesda) 29: 325-333, 2014.
64. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, Hauch A, Lundberg PW, Summers W, Yuan L, et al: Melatonin: An inhibitor of breast cancer. Endocr Relat Cancer 22: R183-R204, 2015.
65. Dai J, Ram PT, Yuan L, Spriggs LL and Hill SM: Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. Mol Cell Endocrinol 176: 111-120, 2001.
66. Reiter RJ, Tan DX, Manchester LC, Lopez-Burillo S, Sainz RM and Mayo JC: Melatonin: Detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol 527: 539-548, 2003.
67. Blask DE, Pelletier DB, Hill SM, Lemus-Wilson A, Grosso DS, Wilson ST and Wise ME: Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117: 526-532, 1991.
68. Tamarkin L, Almeida OF and Danforth DN: Melatonin and malignant disease. Ciba Found Symp 117: 284-299, 1985.
69. Coleman MP and Reiter RJ: Breast cancer, blindness and melatonin. Eur J Cancer 28: 501-503, 1992.
70. Kliukiene J, Tynes T and Andersen A: Risk of breast cancer among norwegian women with visual impairment. Br J Cancer 84: 397-399, 2001.
71. Flynn-Evans EE, Stevens RG, Tabandeth H, Schernhammer ES and Lockey SW: Total visual blindness is protective against breast cancer. Cancer Causes Control 20: 1753-1756, 2009.
72. Schernhammer ES, Laden F, Speizer FE, Willet WC, Hunter DJ, Kawachi I and Colditz GA: Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93: 1563-1568, 2001.
73. González A, Cos S, Martínez-Campa C, Alonso-González C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barceló EJ: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92, 2008.
74. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006.
75. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Rse Treat 94: 249-254, 2005.
76. Cos S, Martínez-Campa C, Mediavilla MD and Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38: 136-142, 2005.
77. Purohit A, Woo LW and Potter BV: Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol 340: 154-160, 2011.
78. Sasano H, Suzuki T, Nakata T and Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer 13: 129-136, 2006.
79. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 8: 691-702, 2008
80. Álvarez-García V, González A, Martínez-Campa C, Alonso-González C and Cos S: Melatonin modulates aromatase activity and expression in endothelial cells. Oncol Rep 29: 2058-2064, 2013.
81. González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr Cancer Drug Targets 10: 279-286, 2010.
82. González A, Martínez-Campa C, Alonso-González C and Cos S: Melatonin affects the dynamic steady-state equilibrium of estrogen sulfates in human umbilical vein endothelial cells by regulating the balance between estrogen sulfatase and sulfotransferase. Int J Mol Med 36: 1671-1676, 2015.
83. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A and Alonso-González C: Melatonin-estrogen interactions in breast cancer. J Pineal Res 38: 217-222, 2005.
84. García Pedrero JM, Del Río B, Martínez-Campa C, Muramatsu M, Lazo PS and Ramos S: Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 16: 947-960, 2002.
85. Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994.
86. Rato AG, Pedrero JG, Martínez MA, del Río B, Lazo PS and Ramos S: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868, 1999.
87. Bouhoute A and Leclercq G: Calmodulin decreases the estrogen binding capacity of the estrogen receptor. Biochem Bioph Res Commun 227: 651-657, 1996.
88. del Río B, García Pedrero JM, Martínez-Campa C, Zuazua P, Lazo PS and Ramos S: Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279: 38294-38302, 2004.
89. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L and Hill SM: Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 179: 141-150, 2002.
90. Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T and Asch HL: Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 118: 451-458, 2002.
91. Aronica SM, Kraus WL and Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91: 8517-8521, 1994.
92. Godson C and Reppert SM: The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology 138: 397-404, 1997.
93. Hill SM, Spriggs LL, Simon MA, Muraoka H and Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64: 249-256, 1992.
94. Cos S and Blask DE: Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res 17: 25-32, 1994.
95. Molis TM, Spriggs LL, Jupiter Y and Hill SM: Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res 18: 93-103, 1995.
96. Hong J, Shah NN, Thomas TJ, Gallo MA, Yurkow EJ and Thomas T: Differential effects of estradiol and its analogs on cyclin D1 and CDK4 expression in estrogen receptor positive MCF-7 and estrogen receptor-transfected MCF-10AEwt5 cells. Oncol Rep 5: 1025-1033, 1998.
97. Cos S, Blask DE, Lemus-Wilson A and Hill AB: Effects of melatonin on the cell kinetics and ‘estrogen-rescue’ of MCF-7 human breast cancer cells in culture. J Pineal Res 10: 36-42, 1991.
98. Mediavilla MD, Cos S and Sánchez-Barceló EJ: Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 65: 415-420, 1999.
99. Alonso-González C, González A, Martínez-Campa C, Menéndez-Menéndez J, Gómez-Arozamena J, García-Vidal A and Cos S: Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis. Cancer Lett 370: 145-152, 2016.
100. Wang SC, Lin SH, Su LK and Hung MC: Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Commun 234: 247-251, 1997.
101. Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR and Pozo D: Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 35: 204-211, 2003.
102. Martínez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A and Sánchez-Barceló EJ: Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 268: 272-277, 2008.
103. Alonso-González C, Mediavilla D, Martínez-Campa C, González A, Cos S and Sánchez-Barceló EJ: Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa). Toxicol Lett 181: 190-195, 2008.
104. Mao L, Yuan L, Slakey LM, Jones FE, Burow ME and Hill SM: Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 12: R107, 2010.
105. Cos S, Fernández R, Güezmes A and Sánchez-Barceló EJ: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390, 1998.
106. Kawaguchi T: Cancer metastasis: Characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. Curr Drug Targets Cardiovasc Haematol Disord 5: 39-64, 2005.
107. Canel M, Serrels A, Frame MC and Brunton VG: E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 126: 393-401, 2013.
108. Gui GP, Puddefoot JR, Vinson GP, Wells CA and Carpenter R: Altered cell-matrix contact: A prerequisite for breast cancer metastasis? Br J Cancer 75: 623-633, 1997.
109. González A, Alvarez-García V, Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes differentiation of 3T3-L1 fibroblasts. J Pineal Res 52: 12-20, 2012.
110. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 52: 282-290, 2012.
111. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res 54: 373-380, 2013.
112. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I and Ilan N: Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279: 23536-23541, 2004.
113. Gu Q, Wang D, Wang X, Peng R, Liu J, Jiang T, Wang Z, Wang S and Deng H: Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. I. The PI3K/AKT pathway and induction of phosphorylation of BAD. Radiat Res 161: 692-702, 2004.
114. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic effects of melatonin in endothelial cell cultures. Microvasc Res 87: 25-33, 2013.
115. Ahmad I and Shagufta: Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. Eur J Med Chem 102: 375-386, 2015
116. Cos S, Álvarez-García V, González A, Alonso-González C and Martínez-Campa C: Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review). Oncol Lett 8: 487-492, 2014.
117. Proietti S, Cucina A, Reiter RJ and Bizarri M: Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci 70: 2139-2157, 2013.
118. Lissoni P, Barni S, Tancini G, Crispino S, Paolorossi F, Lucini V, Mariani M, Cattaneo G, Esposti D, Esposti G, et al: Clinical study of melatonin in untreatable advanced cancer patients. Tumori 73: 475-480, 1987.
119. Grant SG, Melan MA, Latimer JJ and Witt-Enderby PA: Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 11: e5, 2009.
120. Del Fabbro E, Dev R, Hui D, Palmer L and Bruera E: Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A double-blind placebo controlled trial. J Clin Oncol 31: 1271-1276, 2013.
121. Berk L, Berkey B, Rich T, Hrushesky W, Blask D, Gallagher M, Kudrimoti M, McGarry RC, Suh J and Mehta M: Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys 68: 852-857, 2007.
122. Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A and Maestroni G: Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer 5: 126-129, 1997.
123. Vijayalaxmi Thomas CR, Reiter RJ and Herman TS: Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 20: 2575-2601, 2002.
124. Lissoni P: Is there a role for melatonin in supportive care? Support Care Cancer 10: 110-116, 2002.
125. Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F and Tancini G: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35: 1688-1692, 1999.
126. Lissoni P, Chilelli M, Villa S, Cerizza L and Tancini G: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res 35: 12-15, 2003.
127. Sookprasert A, Johns NP, Phunmanee A, Pongthai P, Cheawchanwattana A, Johns J, Konsil J, Plaimee P, Porasuphatana S and Jitpimolmard S: Melatonin in patients with cancer receiving chemotherapy: A randomized, double-blind, placebo-controlled trial. Anticancer Res 34: 7327-7337, 2014.
128. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ and Mills E: Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. Integr Cancer Ther 11: 293-303, 2012.
129. Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ, Dong TF and Fu QL: The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 69: 1213-1220, 2012.
130. Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102: 89-96, 2006.
131. Chakravarthi BV, Nepal S and Varambally S: Genomic and epigenomic alterations in cancer. Am J Pathol 186: 1724-1735, 2016.
132. Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS and Park YS: MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res 51: 345-352, 2011.
133. Lee SE, Kim SJ, Yoon HJ, Yu SY, Yang H, Jeong SI, Hwang SY, Park CS and Park YS: Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin J Pineal Res 54: 80-88, 2013.
134. Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, Anbalagan M, Hauch A, Frasch T, Rowan BG, et al: Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res 74: 4099-4110, 2014.
135. Xiang S, Dauchy RT, Hauch A, Mao L, Yuan L, Wren MA, Belancio VP, Mondal D, Frasch T, Blask DE and Hill SM: Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. J Pineal Res 59: 60-69, 2015.
136. He SM, Li R, Kanwar JR and Zhou SF: Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 18: 439-481, 2011.
137. Granzotto M, Rapozzi V, Decorti G and Giraldi T: Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res 31: 206-213, 2001.
138. Jardim-Perassi BV, Arbab AS, Ferreira LC, Borin TF, Varma NR, Iskander AS, Shankar A, Ali MM and de Campos Zuccari DA: Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One 9: e85311, 2014.
139. Woo SM, Min KJ and Kwon TK: Melatonin-mediated Bim up-regulation and cyclooxygenase-2 (COX-2) down-regulation enhances tunicamycin-induced apoptosis in MDA-MDB-231 cells. J Pineal Res 58: 310-320, 2015.
140. Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F, Kang T, Huang W and Deng W: Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 53: 77-90, 2012.
141. Proietti S, Cucina A, Dobrowolny G, D'Anselmi F, Dinicola S, Masiello MG, Pasqualato A, Palombo A, Morini V, Reiter RJ and Bizarri M: Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J Pineal Res 57: 120-129, 2014.
142. Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J and Kim SH: Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefetinib. Cell Physiol Biochem 34: 865-872, 2014.
143. Plaimee P, Weerapreeyakul N, Barusrux S and Johns NP: Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif 48: 67-77, 2015.
144. Pariente R, Pariente JA, Rodríguez AB and Espino J: Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: Effects on oxidative stress and DNA fragmentation. J Pineal Res 60: 55-64, 2016.
145. Uguz AC, Cig B, Espino J, Bejarano I, Naziroglu M, Rodríguez AB and Pariente JA: Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res 53: 91-98, 2012.
146. Yamanishi M, Narazaki H and Asano T: Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase. Exp Hematol 43: 207-214, 2015.
147. Ma C, Li LX, Zhang Y, Xiang C, Ma T, Ma ZQ and Zhang ZP: Protective and sensitive effects of melatonin combined with Adriamycin on ER+ (estrogen receptor) breast cancer. Eur J Gynaecol Oncol 36: 197-202, 2015.
148. κB activation. J Pineal Res 60: 27-38, 2016.
149. Kosar PA, Naziroğlu M, Övey IS and Çiğ B: Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: Involvement of TRPV1 channels. J Membr Biol 249: 129-140, 2016.
150. Chuffa LG, Alves MS, Martínez M, Camargo IC, Pinheiro PF, Domeniconi RF, Júnior LA and Martinez FE: Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma. Endocr Relat Cancer 23: 65-76, 2016.
151. Li W, Fan M, Chen Y, Zhao Q, Song C, Yan Y, Jin Y, Huang Z, Lin C and Wu J: Melatonin induces cell apoptosis in AGS cells through the activation of JNK and P38 MAPK and the suppression of nuclear factor-kappa B: A novel therapeutic implication for gastric cancer. Cell Physiol Biochem 37: 2323-2338, 2015.
152. Reiter RJ, Tamura H, Tan DX and Xu XY: Melatonin and the circadian system: Contributions to successful female reproduction. Fertil Steril 102: 321-328, 2014.
153. Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ and Yan X: Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget 7: 46768-46784, 2016.
154. Stover DG and Wagle N: Precision medicine in breast cancer: Genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep 17: 15, 2015.
155. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C and Reiter RJ: Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs 21: 819-831, 2012.